Ally Financial Inc. Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Ally Financial Inc. increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 350.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,000 shares of the company's stock after buying an additional 7,000 shares during the period. Eli Lilly and Company accounts for 0.8% of Ally Financial Inc.'s portfolio, making the stock its 24th largest position. Ally Financial Inc.'s holdings in Eli Lilly and Company were worth $6,948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. CWA Asset Management Group LLC lifted its position in Eli Lilly and Company by 11.9% in the 4th quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after acquiring an additional 724 shares in the last quarter. Centerpoint Advisory Group purchased a new position in Eli Lilly and Company in the fourth quarter worth about $514,000. M&T Bank Corp boosted its position in Eli Lilly and Company by 0.7% in the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after purchasing an additional 1,867 shares during the last quarter. Kentucky Trust Co bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $834,000. Finally, Proficio Capital Partners LLC increased its position in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock valued at $5,202,000 after purchasing an additional 1,562 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Trading Up 14.5 %

Eli Lilly and Company stock traded up $106.80 during mid-day trading on Friday, hitting $841.70. The company's stock had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,703. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a 50 day moving average of $829.09 and a 200-day moving average of $820.35. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The stock has a market cap of $798.08 billion, a PE ratio of 71.88, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the subject of a number of recent research reports. Guggenheim cut their price objective on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Truist Financial upped their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Wells Fargo & Company lifted their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Two research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,012.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.